# Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia

> **NCT01266876** · PHASE2 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 77 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Alirocumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01266876
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2015-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01266876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01266876, "Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01266876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*